Ken Langone, co-founder of Home Depot, stated that Eli Lilly stock could reach $2,000 within the next 3 to 4 years, challenging the long-term success of his Home Depot investment. Eli Lilly has shown strong growth, up over 54% in the past year despite a recent pullback, while Home Depot's stock has declined over the same period. Langone credits Eli Lilly's diverse research and acquisitions, especially in immunology, oncology, and neuroscience, as key drivers. He highlighted the company's significant R&D investment and strategic expansion, suggesting continued growth potential for investors.
Ken Langone's confidence in Eli Lilly contrasts with his past success in Home Depot, highlighting different investor sentiments. On Pluang as of Sep 22, 2026 21:21 WIB, Eli Lilly trades at USD 1,162.00 with a slight 1-day decline of 0.21%, while Home Depot is priced at USD 300.57, up 1.14% for the day. Despite Langone's bullish view on Eli Lilly, Pluang users show more buying interest in Home Depot, with 66% buy orders compared to 34% for Eli Lilly.
Eli Lilly reported a strong quarter beating revenue and earnings estimates, driven by its dominant GLP-1 obesity and diabetes drugs Mounjaro and Zepbound. Despite this, the stock fell 7.2% over the past month due to pricing pressures and competition....
Since Medicare began covering obesity drugs in July, 700,000 new seniors have started GLP-1 treatments, with 70% using Eli Lilly's medicines. The coverage, part of a temporary "Bridge" program, allows eligible seniors to access weight loss drugs for ...
Eli Lilly reported a remarkable 48% revenue growth driven by strong sales of Mounjaro and Zepbound, yet its stock price remains nearly flat this year. Despite recent stock volatility due to price cuts, acquisition charges, and competition concerns, a...
Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...
Nvidia and Eli Lilly both exceeded earnings expectations, but Nvidia's AI-driven data center growth offers a stronger long-term investment opportunity. Nvidia posted $96.22 billion in revenue, driven by AI infrastructure demand and supply constraints...
